Home › Companies › KPRX

KIORA PHARMACEUTICALS INC

KPRX Rare disease Lead: Phase 2 3 Biotech Distilled articles ↓

Ophthalmology Small Molecule

Most recent annual filing: 2026-01-15

Pipeline (5 active programs)

KIO-301

Small Molecule Target: potassium and hyperpolarization-activated cyclic nucleotide-gated voltage gated ion channels

Retinitis Pigmentosa Phase 2 Théa Open Innovation

KIO-104

Small Molecule Target: DHODH

Diabetic Macular Edema Phase 2 intravitreal
Posterior Non-Infectious Uveitis Phase 2 intravitreal
Undisclosed indication

KIO-101

Small Molecule Target: DHODH

Ocular Surface Inflammation Phase 1 topical

Biotech Distilled coverage (3)

2026-04-27 UPDATE: KIORA PHARMACEUTICALS INC (KPRX) - Perceptive Shows Up, Nature Medicine Prints, and the Warrant Structure Tells You the Plan 🔒 Paid
2026-03-28 UPDATE: Kiora Pharmaceuticals (KPRX) - A 12-Month Delay, a $4.6M Impairment, and the Value of Deep-Pocketed Partners 🔒 Paid
2026-03-09 Kiora Pharmaceuticals (KPRX): Scientific Deep Dive for KIO-301 and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.